文献速递乳腺癌

分子影像识别从内分泌联合CDK抑制治疗获益的转移性乳腺癌患者

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
PubMed 文献 · Eur J Cancer · 2019-12-28

本研究探索FES-PET异质性和FES摄取是否与来曲唑联合帕博西利治疗ER阳性转移性乳腺癌的结局相关。30例患者基线FES-PET异质性评估显示,100%FES阳性患者中位TTP为73周,异质性阳性为27周,无FES阳性为15周,组间差异无统计学意义(P=0.30)。FES摄取与代谢反应无显著关联,ESR1突变与FES摄取无关。

要点

  • FES-PET异质性可能有助于筛选从来曲唑联合CDK抑制中获益的ER阳性转移性乳腺癌患者。
  • 100%FES阳性患者中位TTP数值上长于异质性阳性及无FES阳性患者,但差异未达统计学意义。
  • FES摄取与8周FDG-PET代谢反应无显著关联,ESR1突变与FES摄取无关。

核心结论

  • 这项探索性研究提示FES-PET异质性可能潜在识别从来曲唑联合CDK抑制治疗中获益的ER阳性转移性乳腺癌患者亚组。

研究设计与样本

  • 探索性研究,纳入30例ER阳性转移性乳腺癌患者,基线行FES-PET和FDG-PET,共评估864个转移灶的FES-PET异质性。
  • 27例患者共688个病灶用于疗效评估,基线采集循环肿瘤DNA进行ESR1突变分析。

主要发现

  • 7例100%FES阳性患者中位TTP为73周(95%CI 21至无穷),20例异质性FES阳性患者为27周(14-49),3例无FES阳性患者为15周(9至无穷),log-rank P=0.30。
  • 代谢进展患者FES摄取几何均数为2.3,代谢稳定患者为2.5(对比进展P=0.82),代谢反应患者为3.3(对比进展P=0.40),趋势P=0.21。
  • ESR1突变在13/23例患者中发现,与FES摄取无关。

临床怎么用

  • FES-PET异质性评分和FES摄取可作为探索性工具,用于评估ER阳性转移性乳腺癌患者的ER表达异质性。
  • 目前数据尚不足以支持FES-PET常规用于筛选来曲唑联合CDK抑制治疗获益人群。

局限性

  • 本研究为探索性研究,样本量小(30例),统计效能有限。
  • FES-PET异质性组间TTP差异无统计学意义(P=0.30),结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding cyclin-dependent kinase (CDK) inhibitor to endocrine treatment improves outcome in œstrogen receptor (ER) positive metastatic breast cancer, but identifying the subset of patients who benefit is challenging. Response is potentially associated with ER expression heterogeneity. This is because, unlike the primary tumour in the breast that is localized to the organ, the metastatic breast cancer has spread and continues to spread to distant locations in the body such as bones, lungs, liver, axial skeleton, even to the central nervous system like the brain, wherefrom obtaining biopsies are not easy, and also, the metastasised tissues are heterogeneous. Positron emission tomography (PET) with 16α-[18F]fluoro-17β-œstradiol (FES), briefly referred to as FES-PET, allows whole-body ER assessment. We explored whether FES-PET heterogeneity and FES uptake were related to letrozole and palbociclib outcome, in patients with ER positive, metastatic breast cancer. PATIENTS AND METHODS: Patients underwent a baseline FES-PET and 18F-fluorodeoxyglucose (FDG) PET, the FDG-PET served to help identify active sites of breast cancer with contrast-enhanced computed tomography (CT). FES-PET heterogeneity score (% FES positive lesions divided by all lesions on FDG-PET and/or CT) and FES uptake were related to outcome and 8-week FDG-PET response. Circulating tumour DNA (CtDNA) samples for ESR1 mutation analysis were collected at baseline. RESULTS: In 30 patients with 864 metastatic lesions, baseline FES-PET heterogeneity was assessed. In 27 patients with 688 lesions, response was evaluated. Median time to progression (TTP) was 73 weeks (95% confidence interval [CI] 21 to ∞) in 7 patients with 100% FES positive disease, 27 weeks (14-49) in heterogeneous FES positive disease (20 patients), and 15 weeks (9 to ∞) without FES positivity (three patients; log-rank P = 0.30). Geometric mean FES uptake was 2.3 for metabolic progressive patients, 2.5 (Pvs progression = 0.82) for metabolic stable disease, and 3.3 (Pvs progression = 0.40) for metabolic response (Ptrend = 0.21). ESR1 mutations, found in 13/23 patients, were unrelated to FES uptake. CONCLUSION: This exploratory study suggests that FES-PET heterogeneity may potentially identify the subset of ER positive, metastatic breast cancer patients who benefit from letrozole combined with CDK inhibition. CLINICAL TRIAL INFORMATION: NCT02806050.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boers J, Venema CM, de Vries EFJ, et al. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer. 2019. PMID: 31891878. doi:10.1016/j.ejca.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。